💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Pegunigalsidase Alfa

CHEMBL4297801 Phase 4 Approuvé Enzyme
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
560.6 g/mol
LogP
-8.0
Phase
4

A PEGylated plant-cell-expressed recombinant alpha-galactosidase A enzyme replacement therapy used to treat Fabry disease, a lysosomal storage disorder. Longer half-life from PEGylation allows biweekly dosing, and it reduces the accumulation of globotriaosylceramide in tissues.

Masse moléculaire

560,6000 g/mol

LogP

-8,00

TPSA

252,00 Ų

Règle des 5 de Lipinski

Non conforme

Mécanisme d'action

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

SMILES

C(CCNC(=O)CCC(=O)NCCOCCNC(=O)CCC(=O)NCCCC[C@@H](C(=O)O)N)C[C@@H](C(=O)O)N

InChI

InChI=1S/C24H44N6O9/c25-17(23(35)36)5-1-3-11-27-19(31)7-9-21(33)29-13-15-39-16-14-30-22(34)10-8-20(32)28-12-4-2-6-18(26)24(37)38/h17-18H,1-16,25-26H2,(H,27,31)(H,28,32)(H,29,33)(H,30,34)(H,35,36)(H,37,38)/t17-,18-/m0/s1

Molecular Formula

C24H44N6O9

HBD / HBA

8 / 11

Liaisons Rotatives

24

Atomes Lourds

39

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A PEGylated plant-cell-expressed recombinant alpha-galactosidase A enzyme replacement therapy used to treat Fabry disease, a lysosomal storage disorder. Longer half-life from PEGylation allows biweekly dosing, and it reduces the accumulation of globotriaosylceramide in tissues.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Pegunigalsidase Alfa is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297801. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 121488171. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.